PUBLIC POLICY STATEMENT

WE SUPPORT ACTION ON PHARMACEUTICALS IN THE ENVIRONMENT

Merck & Co., Inc., Rahway, NJ, USA supports science-based, environmentally sound international and national programs to address the challenges presented by pharmaceuticals in the environment (PIE), including: conducting environmental risk assessments of our products to support drug marketing authorizations, implementing programs to minimize environmental risk from manufacturing discharges, supporting industry efforts to offer medicine disposal programs and supporting research to fill data gaps and advance the science to mitigate the risks of PIE.

Managing Risk in Our Operations

**Environmental Risk Assessments**

Our Company conducts environmental risk assessments of our products from the development phase through product launch to understand and manage potential product impacts from both manufacturing and patient use. We conduct these assessments in accordance with applicable stringent global regulations, including the regulatory review processes of the U.S. Food and Drug Administration and the European Medicines Agency. Product environmental safety profiles are reassessed during periodic renewals of product filings and risk mitigation actions are implemented when needed.

**Manufacturing**

Our Human and Animal Health manufacturing facilities strive to ensure their operations are both compliant and protective of human health and the environment. Our sites incinerate product-containing solid waste streams, unless restricted by local regulation. Our facilities comply with an internal Environmental Quality Criteria (EQC) program that evaluates potential human health and environmental impacts in waterbodies where we discharge wastewater. These standards are based on criteria established in accordance with stringent regulatory review processes. Each facility assesses
the potential risk from operations using industry accepted risk assessment methods, minimizes impacts from process wastewater discharges, and establishes procedures for managing and controlling the discharge of active pharmaceutical ingredients (APIs). Risk minimization measures at Company production facilities may include API treatment technologies when deemed necessary.

Some of our production is performed by external suppliers who share our commitment to ethics and integrity. We communicate our Business Partner Code of Conduct which includes our supplier performance expectations to all contracted external suppliers and provide them available wastewater discharge criteria. In addition, we have adopted the Pharmaceutical Supply Chain Initiative’s (PSCI) Pharmaceutical Industry Principles and encourage our external partners to do the same. In addition, our Company is a signatory to the 10 Principles of the United Nations Global Compact.

We conduct assessments of external suppliers using a risk-based approach based on multiple factors including engagement type, geography, and the potential impact of any identified issues upon our finished products and our customers. These assessments evaluate an external supplier’s ability to meet environmental, health and safety regulatory requirements and industry standards, the PSCI Principles and our Company’s specific standards for ethical business practices. When we identify deficiencies or opportunities for improvement, we collaborate closely with our external suppliers, or potential external suppliers, to close any gaps.

**Supporting Research on PIE and Proper Disposal**

**Research**

We carefully monitor scientific research on the issue of PIE, particularly studies that evaluate the potential effects pharmaceutical products may have on the aquatic environment and human health. We support the use of science-based environmental risk assessments, and we will continue to collaborate with regulatory, academic, health care and research organizations to identify additional data needs on the transport, fate, and effects of PIE. We are a partner with the Innovative Medicines Initiative on PIE (PREMIER), and have committed to providing data for analysis and conducting new studies to fill any identified data gaps.

In addition, we work to reduce the environmental impacts of our products in the process design stage through our Green & Sustainable Science program. By using more efficient processing methods, we can reduce the amount of energy, water and raw materials we use to make our products, while reducing the amount of waste we generate.
**Disposal**

Our Company supports the development of science-based, cost-effective, and environmentally sound programs that promote the proper disposal of unused medicines in accordance with regional requirements. For more information, refer to our public position statement on Responsible Disposal of Medicines in the Household.

**Stakeholder Engagement and Advocacy**

We participate in efforts to address PIE with various organizations, including the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

The EFPIA, the Medicines for Europe, and the Association of the European Self-Medication Industry (AESGP) together developed the Eco-Pharmaco-Stewardship (EPS) initiative. The EPS considers the entire life cycle of a medicine and addresses the roles and responsibilities of all parties including public services, the pharmaceuticals industry, environmental experts, doctors, pharmacists, and patients.

The EPS initiative is supported by the following four ‘pillars’, which have been identified as the initial key areas of focus for the pharmaceutical industry:

1. The identification of the potential environmental risks of existing and new active pharmaceutical ingredients (API) through intelligent and targeted assessment strategies (see above PREMIER initiative);
2. The compilation of best industry practices enabling manufacturers to minimize losses to the environment (see Caldwell et al. 2015 publication “A Risk Based Approach To Manage Active Pharmaceutical Ingredients In Manufacturing Effluent”);
3. The refinement of the existing environmental risk assessment (ERA) process for medicinal products to ensure that they remain up-to-date and relevant; and,
4. The Pharmaceutical Industry support of the EU’s communication activities and awareness campaigns on the appropriate use, storage and disposal of medicines. #MedsDisposal

Our Company actively participates in developing and executing these initiatives by conducting detailed evaluations of our products (old and new), identifying and filling any data gaps, and updating our assessments as needed.
As a member of the AMR Industry Alliance (AMR IA) and signatory to the Industry Roadmap for Progress on Combating Antimicrobial Resistance, we support a common standard for safely manufacturing antibiotics. The standard includes best practices for minimizing discharges as well as development of Predicted No-Effect Concentrations (PNECs) to support environmental risk assessments, which are designed to reduce the selection pressure from antibiotic residues in water and protect ecological species. Additionally, we participate in the AMR IA survey for our own manufacturing sites and our supplier facilities, in order to assess progress against the Framework and meeting the PNECs. For more information related to antibiotics, see our Global Antimicrobial Resistance Action Plan. (https://www.merck.com/wp-content/uploads/sites/5/2021/06/global-antimicrobial-resistance-action-plan.pdf)